Emergent BioSolutions recently received a $19.7 million contract from the Biomedical Advanced Research and Development Authority (BARDA) to develop monoclonal antibodies of the Ebola virus.
The company will be involved in the analytical method and process development activity, and will be conducting small-scale production activity. The company also will be stockpiling cGMP cells for use in the mass manufacturing of the drug substances necessary.
The antibody will be developed at the company's Bayview Campus in Baltimore, Maryland. It is the same facility that developed the company's Ebola vaccine candidate, which is currently in Phase I clinical testing.
"Emergent is pleased to work with BARDA on this contract, which reflects the government's commitment to enhancing public-private partnerships and, together, taking steps to achieve a state of readiness against emerging public health threats," Adam Havey, executive vice president and president of the company's Biodefense division, said. "We look forward to working collaboratively with the government to further this important program."
The antibodies will be produced in CHO cell lines with 2,000 liters as their scale.
BARDA is part of the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services.